Pro Medicus (ASX:PME) share price jumps after FY21 result

Investors are buying up Pro Medicus shares today after its FY21 results…

| More on:
A group of science or medical professionals cheering good news in the lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Pro Medicus Limited (ASX: PME) share price is moving higher in early trade on Wednesday. This follows the healthcare imaging company releasing its full-year results for FY21.

At the time of writing, Pro Medicus shares are fetching $58.42 apiece, up 3.4%.

Pro Medicus share price rises on

  • Revenue from customers increased 19.5% to $67.9 million
  • Underlying profit before tax up 41% to $42.6 million compared to prior year
  • Net profit after tax attributable to shareholders increased 33.7% to $30.9 million
  • Fully franked final dividend of 8 cents per share declared, taking total dividends in FY21 to 15 cents per share
  • Record number of new contracts announced during the year
  • Company remains debt free, increasing cash and other financial assets to $61.8 million, up 42.4%

What happened in FY21 for Pro Medicus

It was another record financial year for the healthcare imaging company valued at a $5.98 billion market capitalisation. Pro Medicus was undeterred by the pandemic, delivering a significant 19.5% increase in revenue from customer contracts — taking the total to $67.9 million.

During the year, sales and implementations initiatives were at an all-time high, demonstrating the minimal impact COVID-19 restrictions had on the business. This enabled the company to cement several milestone contracts in FY21. Some of these include the $25 million 7 year deal with NYU Langone Health and the $40 million 7 year contract with Intermountain Healthcare.

Despite significant currency fluctuations, Pro Medicus' bottom-line earnings came in at $30.9 million — representing an increase of 33.7% on the previous year.

The significant uptick in profit has allowed the board to declare a fully franked final dividend of 8 cents per share. This takes total FY21 dividends to 15 cents per share, giving an indicative yield of 0.26%.

What did management say?

Commenting on the result, Pro Medicus Chief Executive Officer Dr Sam Hupert said:

It was our most successful year by any measure. All of our key financial metrics headed in the right direction. We foreshadowed a step-up in revenue this year despite currency headwinds and lower numbers in the first quarter due to COVID restrictions and we have delivered on that. Margins continued to increase as did our cash and other financial assets. It was also our biggest year in terms of both sales and implementations, laying the
foundation for a further step-up in exam volumes in FY22

Additionally, regarding the company's pipeline potential, Mr Hupert said:

Although we had a record year in terms of new contracts, our pipeline remains very healthy both in terms of quality and quantity. There is a good mix across the spectrum of opportunities; some cloud, some on-premise, some academic and some in the non-academic-IDN space as well as in the for-profit and private sector.

What's next for Pro Medicus?

Pro Medicus did not specify any outlook or guidance for FY22. However, the company remains focused on expanding its customers through its pipeline. Notably, a number of opportunities are for more than one Visage product.

Additionally, Pro Medicus continues to develop products with its AI Accelerator program.

Pro Medicus share price snapshot

The Pro Medicus share price has returned an impressive 131% to shareholders over the past year. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) has climbed 22.8% during the same time frame.

Based on the current share price, Pro Medicus is trading on a 194 times price-to-earnings (P/E) ratio.

Motley Fool contributor Mitchell Lawler owns shares of Pro Medicus Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Earnings Results

A man in a suit smiles at the yellow piggy bank he holds in his hand.
Earnings Results

Westpac shares on watch amid $6.99b profit and new buyback

Has the big four bank delivered the goods for investors this year? Let's find out.

Read more »

Woman inspecting packages.
Earnings Results

This top 50 ASX stock is diving 5% despite a strong outlook

Investors were looking for more.

Read more »

Two male ASX 200 analysts stand in an office looking at various computer screens showing share prices
Earnings Results

Macquarie share price sinks despite $1.6b half year profit and new buyback

How did this investment bank perform during the first half? Let's find out.

Read more »

A woman holds her hand out under a graphic hologram image of a human brain with brightly lit segments and section points.
Earnings Results

Why the BrainChip share price is in the spotlight this week

Today's reaction is in stark contrast to the day of the release.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

2 All Ords ASX healthcare shares making BIG moves on quarterly updates

These two ASX healthcare companies are seeing heavy trading on Thursday.

Read more »

A businesswoman ponders why her boat is sinking in the ocean.
Resources Shares

Lake Resources share price sinks on quarterly cash flow news

Let's take a look at the highlights of the company's Q3 update.

Read more »

Lithium ion batteries
Earnings Results

Needs a recharge: Novonix share price sees red after Q3 earnings

Investors were likely expecting a tad more.

Read more »

chip and tech stocks represented by two computer chips side by side
AI Stocks

Up 237% in 2024, why is the Appen share price racing higher again today?

Investors are bidding up Appen shares again today. But why?

Read more »